Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry.
Allogeneic marrow transplantation is curative therapy for thalassemia, but fewer than 30% of patients have an HLA-identical sibling marrow donor. Selection of alternative donors of hematopoietic stem cells (unrelated individuals or HLA-nonidentical family members) has been aided by establishment of world-wide donor registries now exceeding 3.6 million volunteers and by DNA-based HLA typing to more closely match potential donors. Coupled with improved methods to control graft-versus-host disease and prevent fungal and cytomegalovirus infection, remarkable progress has been made in alternative donor transplantation. For patients 50 years of age or younger, with recently diagnosed chronic myelogenous leukemia (CML) in chronic phase, 1- and 5-year survivals after HLA-A, B, DRB1 identical unrelated marrow transplantation in Seattle are 82% and 74%, respectively. These results are essentially identical to outcome in similar patients given HLA-matched sibling allografts. However, the world-wide number of alternative donor transplants for thalassemia remains limited to date: 4 unrelated and 60 HLA-nonidentical related transplants have been reported to the IBMTR since 1969 with actuarial overall survival of 75%. Using the paradigm of CML, it is likely that access to curative therapy of thalassemia will improve with optimal HLA typing and donor selection early in the course of disease.
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. ksulliva@fhcrc.org
K M
KM
Sullivan
C
C
Anasetti
M
M
Horowitz
P A
PA
Rowlings
E W
EW
Petersdorf
P J
PJ
Martin
R A
RA
Clift
M C
MC
Walters
T
T
Gooley
J
J
Sierra
J E
JE
Anderson
J
J
Bjerke
M
M
Siadak
M E
ME
Flowers
R A
RA
Nash
J E
JE
Sanders
F R
FR
Appelbaum
R
R
Storb
J A
JA
Hansen
D016026:Bone Marrow Transplantation; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007390:International Agencies; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D019520:Living Donors; D012042:Registries; D015996:Survival Rate; D013789:Thalassemia / Q000401:mortality / Q000628:therapy*; D014019:Tissue Donors; D009927:Tissue and Organ Procurement / Q000458:organization & administration*; D014861:Washington